218 related articles for article (PubMed ID: 15006494)
21. Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons.
Jomphe C; Lemelin PL; Okano H; Kobayashi K; Trudeau LE
Eur J Neurosci; 2006 Nov; 24(10):2789-800. PubMed ID: 17116165
[TBL] [Abstract][Full Text] [Related]
22. The electrophysiological effects of neurotensin on spontaneously active neurons in the nucleus accumbens: an in vivo study.
Stowe ZN; Landry JC; Tang Z; Owens MJ; Kinkead B; Nemeroff CB
Synapse; 2005 Dec; 58(3):165-72. PubMed ID: 16108007
[TBL] [Abstract][Full Text] [Related]
23. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
[TBL] [Abstract][Full Text] [Related]
24. Neurotensin NTS1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: relevance for Parkinson's disease and schizophrenia.
Ferraro L; Beggiato S; Borroto-Escuela DO; Ravani L; O'Connor WT; Tomasini MC; Borelli AC; Agnati LF; Antonelli T; Tanganelli S; Fuxe K
Curr Protein Pept Sci; 2014; 15(7):681-90. PubMed ID: 25175457
[TBL] [Abstract][Full Text] [Related]
25. Neurotensin effects on N-type calcium currents among rat pallidal neurons: an electrophysiological and immunohistochemical study.
Martorana A; Martella G; D'Angelo V; Fusco FR; Spadoni F; Bernardi G; Stefani A
Synapse; 2006 Oct; 60(5):371-83. PubMed ID: 16838364
[TBL] [Abstract][Full Text] [Related]
26. Multitasking with neurotensin in the central nervous system.
Dobner PR
Cell Mol Life Sci; 2005 Sep; 62(17):1946-63. PubMed ID: 16003489
[TBL] [Abstract][Full Text] [Related]
27. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
Goto Y; Grace AA
Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
[TBL] [Abstract][Full Text] [Related]
28. The regulatory role of neurotensin on the hypothalamic-anterior pituitary axons: emphasis on the control of thyroid-related functions.
Stolakis V; Kalafatakis K; Botis J; Zarros A; Liapi C
Neuropeptides; 2010 Feb; 44(1):1-7. PubMed ID: 19878995
[TBL] [Abstract][Full Text] [Related]
29. Neurotensin: A role in substance use disorder?
Ferraro L; Tiozzo Fasiolo L; Beggiato S; Borelli AC; Pomierny-Chamiolo L; Frankowska M; Antonelli T; Tomasini MC; Fuxe K; Filip M
J Psychopharmacol; 2016 Feb; 30(2):112-27. PubMed ID: 26755548
[TBL] [Abstract][Full Text] [Related]
30. Neurotensin agonists as an alternative to antipsychotics.
Boules M; Fredrickson P; Richelson E
Expert Opin Investig Drugs; 2005 Apr; 14(4):359-69. PubMed ID: 15882113
[TBL] [Abstract][Full Text] [Related]
31. Neurotensin and pain modulation.
Dobner PR
Peptides; 2006 Oct; 27(10):2405-14. PubMed ID: 16870306
[TBL] [Abstract][Full Text] [Related]
32. NMR solution structure of neurotensin in membrane-mimetic environments: molecular basis for neurotensin receptor recognition.
Coutant J; Curmi PA; Toma F; Monti JP
Biochemistry; 2007 May; 46(19):5656-63. PubMed ID: 17441729
[TBL] [Abstract][Full Text] [Related]
33. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Miyamoto S; Duncan GE; Marx CE; Lieberman JA
Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
[TBL] [Abstract][Full Text] [Related]
34. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions.
Kasckow J; Nemeroff CB
Regul Pept; 1991 Oct; 36(2):153-64. PubMed ID: 1666685
[TBL] [Abstract][Full Text] [Related]
35. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
[TBL] [Abstract][Full Text] [Related]
36. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.
Pillai A
Neurosignals; 2008; 16(2-3):183-93. PubMed ID: 18253057
[TBL] [Abstract][Full Text] [Related]
37. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
Sharma RP; Janicak PG; Bissette G; Nemeroff CB
Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
[TBL] [Abstract][Full Text] [Related]
38. Neurotensin receptor agonists and antagonists for schizophrenia.
Richelson E; Fredrickson PA; Boules MM
Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
[No Abstract] [Full Text] [Related]
39. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes.
Kitabgi P
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):764-76. PubMed ID: 12630297
[TBL] [Abstract][Full Text] [Related]
40. [The search of small molecules with antipsychotic activity on the background of neurotensin].
Ostrovskaia RU; Gudasheva TA; Krupina NA; Seredin SB
Bioorg Khim; 2012; 38(1):119-26. PubMed ID: 22792715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
